{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:26:19Z","timestamp":1794108379187,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273812"],"award-info":[{"award-number":["82273812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Interdisciplinary Innovation Team of Traditional Chinese Medicine","award":["ZYYCXTD-D-202209"],"award-info":[{"award-number":["ZYYCXTD-D-202209"]}]},{"name":"Sichuan Outstanding Youth Fund Project","award":["23NSFJQ0099"],"award-info":[{"award-number":["23NSFJQ0099"]}]},{"name":"Natural Science Foundation Project of Sichuan Provinc","award":["2023NSFSC1159"],"award-info":[{"award-number":["2023NSFSC1159"]}]},{"name":"Hong Kong RGC Theme-based Research Scheme","award":["T12-201\/20-R"],"award-info":[{"award-number":["T12-201\/20-R"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted delivery and precise release of toxins is a prospective strategy for the treatment of triple-negative breast cancer (TNBC), yet the flexibility to incorporate both properties simultaneously remains tremendously challenging in the X-drug conjugate fields. As critical components in conjugates, linkers could flourish in achieving optimal functionalities. Here, we pioneered a pH-hypersensitive tumor-targeting aptamer AS1411-triptolide conjugate (AS-TP) to achieve smart release of the toxin and targeted therapy against TNBC. The multifunctional acetal ester linker in the AS-TP site-specifically blocked triptolide toxicity, quantitatively sustained aptamer targeting, and ensured the circulating stability. Furthermore, the aptamer modification endowed triptolide with favorable water solubility and bioavailability and facilitated endocytosis of conjugated triptolide by TNBC cells in a nucleolin-dependent manner. The integrated superiorities of AS-TP promoted the preferential intra-tumor triptolide accumulation in xenografted TNBC mice and triggered the in-situ triptolide release in the weakly acidic tumor microenvironment, manifesting striking anti-TNBC efficacy and virtually eliminated toxic effects beyond clinical drugs. This study illustrated the therapeutic potential of AS-TP against TNBC and proposed a promising concept for the development of nucleic acid-based targeted anticancer drugs.<\/jats:p>","DOI":"10.1186\/s13046-024-03133-5","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:02:28Z","timestamp":1721890948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer"],"prefix":"10.1186","volume":"43","author":[{"given":"Yao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuening","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-8682","authenticated-orcid":false,"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"3133_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"key":"3133_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020. https:\/\/doi.org\/10.1016\/j.phrs.2020.104683.","journal-title":"Pharmacol Res"},{"key":"3133_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.02.006","author":"S-H Hwang","year":"2019","unstructured":"Hwang S-H, Park S, Kwan Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.02.006.","journal-title":"Pharmacol Ther"},{"key":"3133_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J, Bian X. Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"3133_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdy547","volume":"30","author":"S Luen","year":"2019","unstructured":"Luen S, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdy547.","journal-title":"Ann Oncol"},{"key":"3133_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01565-6","author":"F Li","year":"2017","unstructured":"Li F, et al. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun. 2017. https:\/\/doi.org\/10.1038\/s41467-017-01565-6.","journal-title":"Nat Commun"},{"key":"3133_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.213077","author":"K Ghasemii","year":"2022","unstructured":"Ghasemii K, et al. Advances in aptamer-based drug delivery vehicles for cancer therapy. Biomaterials Adv. 2022. https:\/\/doi.org\/10.1016\/j.bioadv.2022.213077.","journal-title":"Biomaterials Adv"},{"key":"3133_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202114016","author":"C Jin","year":"2022","unstructured":"Jin C, et al. Engineering enzyme-cleavable oligonucleotides by automated solid\u2010phase incorporation of cathepsin B sensitive dipeptide linkers. Angew Chem Int Ed. 2022. https:\/\/doi.org\/10.1002\/anie.202114016.","journal-title":"Angew Chem Int Ed"},{"key":"3133_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.199","author":"J Zhou","year":"2016","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discovery. 2016. https:\/\/doi.org\/10.1038\/nrd.2016.199.","journal-title":"Nat Rev Drug Discovery"},{"key":"3133_CR10","doi-asserted-by":"publisher","DOI":"10.1039\/d0cs00518e","author":"S Yeldell","year":"2020","unstructured":"Yeldell S, Seitz O. Nucleic acid constructs for the interrogation of multivalent protein interactions. Chem Soc Rev. 2020. https:\/\/doi.org\/10.1039\/d0cs00518e.","journal-title":"Chem Soc Rev"},{"key":"3133_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202003563","author":"L Li","year":"2020","unstructured":"Li L, et al. Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angew Chem Int Ed. 2020. https:\/\/doi.org\/10.1002\/anie.202003563.","journal-title":"Angew Chem Int Ed"},{"key":"3133_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081683","author":"S Ni","year":"2017","unstructured":"Ni S, et al. Chemical modifications of nucleic acid aptamers for therapeutic purposes. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18081683.","journal-title":"Int J Mol Sci"},{"key":"3133_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2015.03.023","author":"CM Berger","year":"2015","unstructured":"Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer. Biochimie. 2015. https:\/\/doi.org\/10.1016\/j.biochi.2015.03.023.","journal-title":"Biochimie"},{"key":"3133_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-019-0655-3","author":"I Rishal","year":"2019","unstructured":"Rishal I, Fainzilber M. Cell size sensing\u2014a one-dimensional solution for a three-dimensional problem? BMC Biol. 2019. https:\/\/doi.org\/10.1186\/s12915-019-0655-3.","journal-title":"BMC Biol"},{"key":"3133_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2008.03.016","author":"EM Reyes-Reyes","year":"2008","unstructured":"Reyes-Reyes EM, Akiyama SK. Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells. Exp Cell Res. 2008. https:\/\/doi.org\/10.1016\/j.yexcr.2008.03.016.","journal-title":"Exp Cell Res"},{"key":"3133_CR16","doi-asserted-by":"publisher","DOI":"10.7150\/thno.16532","author":"Y Wang","year":"2017","unstructured":"Wang Y, et al. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics. 2017. https:\/\/doi.org\/10.7150\/thno.16532.","journal-title":"Theranostics"},{"key":"3133_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601046","author":"D Angelov","year":"2006","unstructured":"Angelov D, et al. Nucleolin is a histone chaperone with FACT-like activity and assists remodeling of nucleosomes. EMBO J. 2006. https:\/\/doi.org\/10.1038\/sj.emboj.7601046.","journal-title":"EMBO J"},{"key":"3133_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0045-6","author":"JE Rosenberg","year":"2013","unstructured":"Rosenberg JE, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investig New Drugs. 2013. https:\/\/doi.org\/10.1007\/s10637-013-0045-6.","journal-title":"Investig New Drugs"},{"key":"3133_CR19","doi-asserted-by":"publisher","unstructured":"Bates P, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. Biochimica et Biophysica Acta (BBA) - General Subjects. 2017. https:\/\/doi.org\/10.1016\/j.bbagen.2016.12.015.","DOI":"10.1016\/j.bbagen.2016.12.015"},{"key":"3133_CR20","unstructured":"Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK; Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res April. 2002;8(4):1284\u20131291."},{"key":"3133_CR21","doi-asserted-by":"publisher","unstructured":"He Z, et al. Chapter 8 - Combination strategies for targeted delivery of nanoparticles for cancer therapy. In: mohapatra SS. et al, editors. Applications of targeted nano drugs and delivery systems. Elsevier; 2019. pp. 191\u2013219. https:\/\/doi.org\/10.1016\/B978-0-12-814029-1.00008-9.","DOI":"10.1016\/B978-0-12-814029-1.00008-9"},{"key":"3133_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.05.011","author":"S Samaresh","year":"2017","unstructured":"Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK. Advances in antibody\u2013drug conjugates: a new era of targeted cancer therapy. Drug Discovery Today. 2017. https:\/\/doi.org\/10.1016\/j.drudis.2017.05.011.","journal-title":"Drug Discovery Today"},{"key":"3133_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Therapy. 2022. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Therapy"},{"key":"3133_CR24","doi-asserted-by":"publisher","DOI":"10.1021\/bc000110v","author":"X Guo","year":"2001","unstructured":"Guo X, Szoka FC. Steric stabilization of fusogenic liposomes by a Low-pH sensitive PEG\u2009\u2013\u2009diortho ester\u2009\u2013\u2009lipid conjugate. Bioconjug Chem. 2001. https:\/\/doi.org\/10.1021\/bc000110v.","journal-title":"Bioconjug Chem"},{"key":"3133_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2017.12.006","author":"D Zhi","year":"2018","unstructured":"Zhi D, et al. A review on cationic lipids with different linkers for gene delivery. Adv Colloid Interface Sci. 2018. https:\/\/doi.org\/10.1016\/j.cis.2017.12.006.","journal-title":"Adv Colloid Interface Sci"},{"key":"3133_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.05.032","author":"W Hou","year":"2019","unstructured":"Hou W, Liu B, Xu H. Triptolide: medicinal chemistry, chemical biology and clinical progress. Eur J Med Chem. 2019. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.032.","journal-title":"Eur J Med Chem"},{"key":"3133_CR27","doi-asserted-by":"publisher","DOI":"10.2174\/1389200219666180816141506","author":"W Song","year":"2019","unstructured":"Song W, et al. Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019. https:\/\/doi.org\/10.2174\/1389200219666180816141506.","journal-title":"Curr Drug Metab"},{"key":"3133_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.03.002","author":"P Noel","year":"2019","unstructured":"Noel P, et al. Triptolide and its derivatives as Cancer therapies. Trends Pharmacol Sci. 2019. https:\/\/doi.org\/10.1016\/j.tips.2019.03.002.","journal-title":"Trends Pharmacol Sci"},{"key":"3133_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114694","author":"D Kang","year":"2022","unstructured":"Kang D, et al. Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia. Eur J Med Chem. 2022. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114694.","journal-title":"Eur J Med Chem"},{"key":"3133_CR30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00914","author":"T Tian","year":"2018","unstructured":"Tian T, Song Y, Li K, Sun Y, Wang Q. Synthesis, characterization, and evaluation of triptolide cell-penetrating peptide derivative for transdermal delivery of triptolide. Mol Pharm. 2018. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00914.","journal-title":"Mol Pharm"},{"key":"3133_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135229","author":"S Najafi","year":"2023","unstructured":"Najafi S, Moshtaghie AA, Hassanzadeh F, Nayeri H, Jafari E. Design, synthesis, and biological evaluation of novel atorvastatin derivatives. J Mol Struct. 2023. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135229.","journal-title":"J Mol Struct"},{"key":"3133_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107158","author":"E Doron\u2010Mandel","year":"2021","unstructured":"Doron\u2010Mandel E, et al. The glycine arginine-rich domain of the RNA\u2010binding protein nucleolin regulates its subcellular localization. EMBO J. 2021. https:\/\/doi.org\/10.15252\/embj.2020107158.","journal-title":"EMBO J"},{"key":"3133_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.07.005","author":"RBT Perry","year":"2016","unstructured":"Perry RBT, et al. Nucleolin-mediated RNA localization regulates Neuron Growth and Cycling Cell size. Cell Rep. 2016. https:\/\/doi.org\/10.1016\/j.celrep.2016.07.005.","journal-title":"Cell Rep"},{"key":"3133_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/01478885.2019.1592832","volume":"42","author":"A Jafri","year":"2019","unstructured":"Jafri A, et al. Phytochemical screening of Sterculia foetida seed extract for anti-oxidant, anti-microbial activity, and detection of apoptosis through reactive oxygen species (ROS) generation, mitochondrial membrane potential (MMP) decrease, and nuclear fragmentation in human osteosarcoma cells. J Histotechnology. 2019;42:68\u201379. https:\/\/doi.org\/10.1080\/01478885.2019.1592832.","journal-title":"J Histotechnology"},{"key":"3133_CR35","doi-asserted-by":"publisher","unstructured":"Lim MLR, Lum MG., Hansen TM, Roucou X, Nagley P. On the release of cytochrome c from mitochondria during cell death signaling. J Biomed Sci. 2002;9(6):488\u2013506. https:\/\/doi.org\/10.1159\/000064722.","DOI":"10.1159\/000064722"},{"key":"3133_CR36","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.30.702","author":"F Shao","year":"2007","unstructured":"Shao F, Wang G, Xie H, Zhu X, Sun J, A J. Pharmacokinetic study of Triptolide, a constituent of immunosuppressive Chinese Herb Medicine, in rats. Biol Pharm Bull. 2007. https:\/\/doi.org\/10.1248\/bpb.30.702.","journal-title":"Biol Pharm Bull"},{"key":"3133_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.03.002","author":"C Liu","year":"2024","unstructured":"Liu C, et al. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3K\u03b1 inhibitors. J Adv Res. 2024. https:\/\/doi.org\/10.1016\/j.jare.2024.03.002.","journal-title":"J Adv Res"},{"key":"3133_CR38","doi-asserted-by":"publisher","unstructured":"Talekar M, Ouyang Q, Goldberg MS, Amiji MM. Data from cosilencing of PKM-2 and MDR-1 sensitizes multidrug-resistant ovarian cancer cells to paclitaxel in a murine model of ovarian cancer. American association for cancer research. Collection. 2023. https:\/\/doi.org\/10.1158\/1535-7163.c.6536959.v1.","DOI":"10.1158\/1535-7163.c.6536959.v1"},{"key":"3133_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116183","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis. Eur J Med Chem. 2024. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116183.","journal-title":"Eur J Med Chem"},{"key":"3133_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13130","author":"L Dai","year":"2021","unstructured":"Dai L, et al. Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer. Cell Prolif. 2021. https:\/\/doi.org\/10.1111\/cpr.13130.","journal-title":"Cell Prolif"},{"key":"3133_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.847901","author":"W Xiong","year":"2022","unstructured":"Xiong W, et al. Dacarbazine-loaded targeted polymeric nanoparticles for enhancing malignant melanoma therapy. Front Bioeng Biotec. 2022. https:\/\/doi.org\/10.3389\/fbioe.2022.847901.","journal-title":"Front Bioeng Biotechnol"},{"key":"3133_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.1015","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, et al. A phase Ib\/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1). J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.1015.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3133_CR43","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.annonc.2020.08.2064","volume":"31","author":"EL Mayer","year":"2020","unstructured":"Maye EL, et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2064.","journal-title":"Ann Oncol"},{"key":"3133_CR44","unstructured":"Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002;8(8):2666\u20132674."},{"key":"3133_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202104341","author":"H Xiong","year":"2021","unstructured":"Xiong H, Liu L, Wang Y, Jiang H, Wang X. Engineered aptamer-organic amphiphile self\u2010assemblies for biomedical applications: progress and challenges. Small. 2021. https:\/\/doi.org\/10.1002\/smll.202104341.","journal-title":"Small"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03133-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:07:10Z","timestamp":1721891230000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3133"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03133-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that they have no conflicts of interest with respect to the work described in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"207"}}